Clear Filter

Oct 28, 2022

NORTH CHICAGO, Ill., Oct. 28, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Medicines Agency (EMA) has validated a Marketing Authorization Application (MAA) for epcoritamab (DuoBody®-CD3xCD20), an investigational subcutaneous bispecific antibody, for the treatment of adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. Additionally, Genmab has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for epcoritamab for the treatment of adult patients with R/R large B-cell lymphoma (LBCL) after two or more lines of systemic therapy.

Oct 28, 2022

NORTH CHICAGO, Ill., Oct. 28, 2022 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the third quarter ended September 30, 2022.

Oct 24, 2022

NORTH CHICAGO, Ill., Oct. 24, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that 26 abstracts across its gastroenterology portfolio will be presented at the American College of Gastroenterology (ACG) Annual Scientific Meeting, October 21-26, 2022, in Charlotte, N.C., and virtually.

Oct 21, 2022

NORTH CHICAGO, Ill., Oct. 21, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announces that the U.S. Food and Drug Administration (FDA) has approved RINVOQ® (upadacitinib 15 mg, once daily), an oral therapy, for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation who have had an inadequate response or intolerance to tumor necrosis factor (TNF) blocker therapy. This additional indication follows the FDA approval of RINVOQ in April of this year for adults with active ankylosing spondylitis (AS) who have had an inadequate response or intolerance to one or more TNF blockers, making it the first and only JAK inhibitor that is approved for both conditions.1

Oct 20, 2022

-- DJS Antibodies' DJS-002 is a potential first-in-class antibody directed to LPAR1, currently in investigational preclinical studies for the treatment of Idiopathic Pulmonary Fibrosis and other fibrotic diseases

Oct 18, 2022

IRVINE, Calif., Oct. 18, 2022 /PRNewswire/ -- Today Allergan Aesthetics, an AbbVie company, announces its fourth-consecutive year of partnership with Girls Inc. to support the engagement of high school aged girls interested in exploring a future in STEM (science, technology, engineering, and math).

Oct 17, 2022

NORTH CHICAGO, Ill., Oct. 17, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that Laura J. Schumacher, vice chairman of external affairs and chief legal officer, will retire from the company after a period of transition, following a distinguished 32-year career at AbbVie and its predecessor company Abbott. The company also announced that Perry C. Siatis, who currently serves as senior vice president and deputy general counsel, will assume the role of executive vice president, general counsel and secretary.

Oct 07, 2022

Data results shared across facial injectables, body contouring and skincare portfolio highlights Allergan Aesthetics' continued commitment to advancing aesthetic medicine
Analyses of 15 years of post-marketing surveillance data demonstrate the global reported rate of delayed-onset nodules associated with dermal fillers on the Vycross technology platform is low (<0.016%).
–Results from 3 clinical studies showcasing a customizable platform with patent-pending LTN Complex, to address the appearance of facial hyperpigmentation in a wide range of demographic populations
–Dr. DiAnne Davis to discuss the new Forces of Beauty® Report from the DREAM (Driving Racial Equity in Aesthetic Medicine) Initiative® and at Diversity, Equity and Inclusion (DEI) reception

Oct 04, 2022

NORTH CHICAGO, Ill., Oct. 4, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its third-quarter 2022 financial results on Friday, October 28, 2022, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. CT. It will be accessible through AbbVie's Investor Relations website An archived edition of the session will be available later that day.

Sep 29, 2022

NORTH CHICAGO, Ill., Sept. 29, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today revealed the spectrum of new data from studies of risankizumab (SKYRIZI®) in Crohn's disease and upadacitinib (RINVOQ®) in ulcerative colitis and Crohn's disease that will be presented as live presentations and e-Posters at the United European Gastroenterology (UEG) Week 2022, October 8-11 in Vienna and online. In total, AbbVie is presenting 17 abstracts across a broad range of studies in inflammatory bowel disease (IBD).